Bertolini F, Thomas T, Battaglia M, Gibelli N, Pedrazzoli P, Robustelli della Cuna G
Division of Medical Oncology, IRCCS Maugeri Foundation, Pavia Medical Center, Italy.
Bone Marrow Transplant. 1997 Mar;19(6):615-9. doi: 10.1038/sj.bmt.1700709.
To evaluate a new 'two step' method for purging T, B and neoplastic cells from hematopoietic progenitor cells (PC), PCs were collected by apheresis and some suspensions were deliberately contaminated with 2-5% breast cancer cells. PCs were first processed through CellPro columns for positive selection of cells that express CD34. After this first step, the mean CD34+ cell recovery was 68 +/- 12%, and CD34+ cell purity was 61 +/- 11%; CD3+ and neoplastic cell depletion were 2.1 +/- 0.4 and 1.9 +/0 0.4 logs, respectively. Cells were further processed through the StemSep device for direct depletion of T and B cells or of breast cancer cells. After the first and the second step, overall CD34+ cell recovery was 50 +/- 7%, T and B cell removal was 4.7 +/- 0.4 log and neoplastic cell purging was 4.4 +/- 0.3 log, ie significantly superior to methods described in the past.
为评估一种从造血祖细胞(PC)中清除T细胞、B细胞和肿瘤细胞的新“两步”方法,通过单采术收集PC,并故意用2%-5%的乳腺癌细胞污染一些细胞悬液。首先将PC通过CellPro柱进行处理,以阳性选择表达CD34的细胞。在第一步之后,CD34+细胞的平均回收率为68±12%,CD34+细胞纯度为61±11%;CD3+细胞和肿瘤细胞的清除率分别为2.1±0.4和1.9±0.4对数级。细胞再通过StemSep装置进一步处理,以直接清除T细胞、B细胞或乳腺癌细胞。在第一步和第二步之后,CD34+细胞的总体回收率为50±7%,T细胞和B细胞的清除率为4.7±0.4对数级,肿瘤细胞的清除率为4.4±0.3对数级,即明显优于过去描述的方法。